Iowa State University Capstones, Theses and Graduate Theses and Dissertations Dissertations 2012 Allosteric Mechanisms in Recombinant Human Hexokinase Type I Lu Shen Iowa State University Follow this and additional works at: https://lib.dr.iastate.edu/etd Part of the Biochemistry Commons Recommended Citation Shen, Lu, "Allosteric Mechanisms in Recombinant Human Hexokinase Type I" (2012). Graduate Theses and Dissertations. 12455. https://lib.dr.iastate.edu/etd/12455 This Dissertation is brought to you for free and open access by the Iowa State University Capstones, Theses and Dissertations at Iowa State University Digital Repository. It has been accepted for inclusion in Graduate Theses and Dissertations by an authorized administrator of Iowa State University Digital Repository. For more information, please contact [email protected]. Allosteric mechanisms in recombinant human hexokinase type I by Lu Shen A dissertation submitted to the graduate faculty In partial fulfillment of the requirements for the degree of DOCTOR OF PHILOSOPHY Major: Biochemistry Program of Study Committee: Richard B. Honzatko, Major Professor Scott W. Nelson Mark S. Hargrove Michael Shorgen-Knaak Mei Hong Iowa State University Ames, Iowa 2012 Copyright @ Lu Shen, 2012. All rights reserved. ii Table of Contents Abbreviations v Abstract vi Chapter I. General Introduction & Literature Review Evolution of Hexokinase I Family 1 General Kinetics Properties of Mammalian Hexokinases 2 Tissue Distribution of Mammalian Hexokinases 3 Physiological functions of hexokinase type I 3 X-ray Crystallography Structure of HKI 4 Glc-6-P Inhibition Mechanism Puzzle of HKI 6 Table 8 Figure 9 Thesis Organization 12 References 13 Chapter II. Inhibitor Sites of Unequal Affinity Linked by Binding Synergism in Mutant Forms of Recombinant Human Hexokinase Type-I Abstract 17 Introduction 18 Materials and Methods 20 Results 25 Discussion 30 Table 35 Figure 42 References 52 iii Chapter III. Determination of Site Affinity Constants for Product Inhibition Wild -type and Mutant forms of Recombinant Human Hexokinase Type I Abstract 56 Introduction 56 Materials and Methods 59 Results 62 Discussion 65 Table 71 Figure 79 References 85 Chapter IV. Glucose as a Modulator of Inhibition in Recombinant Human Hexokinase Type I Abstract 89 Introduction 90 Materials and Methods 93 Results 96 Discussion 101 Table 107 Figure 111 References 117 Chapter V. Tracking Allosteric Pathways in Human Hexokinase Type I by Directed Mutation Abstract 121 Introduction 121 Materials and Methods 124 iv Results 127 Discussion 130 Table 133 Figure 137 References 146 Chapter VI. General Conclusions 150 Acknowledgements 152 v Abbreviations HKI: hexokinase I Glc-6-P: glucose 6-phosphate Glc: glucose Pi: phosphate 1,5-anhydroGlc-6-P: 1,5-anhydroglucitol 6-phosphate 2-deoxy Glc-6-P: 2-deoxy glucose-6-phosphate Man-6-P: mannose 6-phosphate Glc-1,6-P2: glucose 1,6-bisphosphate TNP-ADP: 2’-(or-3’)-O-(2,4,6-trinitrophenyl)-adenosine 5’-diphosphate To indicate amino acids in protein sequences or names of the mutant enzymes, one letter or three letters abbreviation was used. vi Abstract Hexokinase I (HKI) is the pacemaker of glycolysis in brain and red bold cells, being subject to potent feedback inhibition by its product glucose 6-phosphate (Glc-6-P) and the relief of that inhibition by inorganic phosphate (Pi) and glucose (Glc). Presented here is a comprehensive model of inhibition and relief of inhibition for recombinant human HKI derived from crystal structures, molecular dynamics simulations, kinetics and directed mutations. Ligand interactions at each half of HKI are comparable in crystal structures, but in simulations, 2-deoxyglucose 6-phosphate (2-deoxyGlc-6-P) and mannose 6-phosphate (Man- 6-P) lose hydrogen bonds at the C-terminal half, consistent with early stages of ligand dissociation. 1,5-Anhydroglucose 6-phosphate (1,5-anhydroGlc-6-P), adopts an alternative binding mode, and stabilizes a slightly open C-terminal half. The kinetics of D413N and/or D861N enzymes (D413 and D861 interact with the 1-OH group of Glc-6-P) are consistent only with synergistic binding of two molecules of 1,5-anhydro-Glc-6-P to sites with unequal constants of dissociation. The crystal structure and simulation of HKI with glucose 1,6- bisphosphate (Glc-1,6-P2) implicate Lys418 (N-terminal half) and Lys866 (C-terminal half) in stabilizing inhibited conformations of HKI, a finding support by directed mutations. Pi displaces 1,5-anhydroglucitol 6-phosphate from the N-terminal half, but not from the C- terminal half. Glucose (Glc) up to concentration of 1 mM interacts synergistically with 1,5- anhydroGlc-6-P, but at higher concentrations becomes an antagonist of inhibition. A site- affinity model quantitatively accounts for these observed phenomena in wild-type and mutant forms of HKI. For wild-type HKI, inhibitor binds to sites of unequal affinity, coupled by negative coorperativity, with the site of highest affinity at the N-terminal half. Pi-displaces inhibitor from the N-terminal half, but does not prevent inhibition at the C-terminal half. Potent inhibition requires two molecules of bound glucose to HKI, and the binding of Glc to the active site seems primarily responsible for creating a state of HKI susceptible to potent inhibition. The mapping of mutations that affect allosteric mechanism in HKI clearly define the N-terminal inhibitor pocket and the flexible subdomain as key components of allostery in HKI. 1 Chapter I. General Introducation & Literature Review Hexokinase (ATP: D-hexose 6-phosphotransferase, EC2.7.1.1) catalyzes the initial and crucial step of glycolysis, the phosphorylation of 6-hydroxyl group of glucose (Glc) using [ATP-Mg]2– as the phosphoryl donor[1-3]. Glucose + [ATP•Mg]2– Glc-6-P2– + [ADP•Mg]1– + H+ The focus of work here is human hexokinase Type I (HKI), and as the name implies, HKI can phosphorylate several six-carbon sugars (mannose, 2-deoxy glucose, and 2,5-anhydro- glucitol, for example); however, only Glc binds to HKI with high affinity. As early as 1954, Crane demonstrated the importance of the 2-hydroxyl group in the binding of 6- phosphorylated hexoses to an inhibitory site of HKI, whereas the 2-hydroxyl group was not important for substrate binding[4]. Only the 4-hydroxyl group is important for both hexose and hexose-6-phosphate binding[4]. Later studies showed that a doubly charged anionic group at the 6-position is necessary for effective inhibition[4-6]. A 5-thio group increases the binding affinities, both for the hexose and hexose-6-phosphate[6]. ATP is the best substrate for HKI (highest kcat, lowest Km). The Km values for other triphosphate nucleosides, such as ITP, GTP, CTP and UTP do not differ significantly from that of ATP, while the kcat values are significantly lower[7]. Evolution of Hexokinase Family Four isozymes of hexokinase have been identified in mammalian tissues[8](Table I). The type I, II and III hexokinase isozymes, all with molecular weights of approximately 100 kDa, share 70% sequence identity[9]. N- and C- halves of isozymes I–III show extensive internal sequence similarity (~50% sequence identity) and structure similarity[9]. Hexokinase Type IV, commonly named glucokinase, is similar to yeast hexokinase isoforms A and B, having a molecular weight of 50 kDa, and exhibiting significant sequence similarity to both halves of isozymes I–III[9]. Presumably, all members in the hexokinase family derived from a common ancestor, a 30 kDa glucomannokinase-like enzyme which utilized poly(P) as substrate in primordial age before the appearance of ATP (Figure 1)[10]. One branch of the evolutionary 2 pathway led to poly(P)/ATP utilizing hexokinase, whereas the other led to a 50 kDa ATP- specific hexokinase such as yeast hexokinase and hexokinase IV[10]. Whether the 50 kDa ATP-specific hexokinase, however, evolved independently from the 30 kDa glucomannokinase-like enzyme or from the poly(P)/ATP utilizing hexokinase is unclear. During evolution, the ATP-specific hexokinase acquired a new property of regulation, feedback inhibition by product, just like the isoforms in starfish and other marine organisms[9-10]. The 100 kDa hexokinase architecture appeared then through gene duplication and fusion[11-14]. The N-domain lost catalytic properties in becoming mammalian hexokinase types I and III[10]. The 100 kDa Glc-6-P insensitive hexokinase might have evolved directly from the 50 kDa Glc-6-P insensitive enzyme, or from the 50/100 kDa Glc-6-P sensitive enzyme, thereafter losing product inhibition. Some researchers suggest that the gene duplication and fusion occurred prior to the diversification of the hexokinase family, and that glucokinase evolved from the 100 kDa isozyme by losing its N-terminal regulatory domain[15]. General Kinetics Properties of Mammalian Hexokinases Besides sequence and structural similarities, isozymes I-III also share several properties, such as Km for glucose is in the sub-millimolar range and product inhibition is at physiologically relevant concentrations (micromolar level)[9]; however, they differ significantly in catalytic and regulatory properties. Both halves of hexokinase II possess catalytic activity[16], whereas the N-halves of hexokinase I and III are devoid of activity[9, 17-18]. Given the fact that both hexokinase I and II have special binding sites for Glc, Glc-6-P, Pi and ATP in both N- and C- domains, it is believed that during evolution, the N-terminal domain of hexokinase I lost its [9] activity and evolved into a regulatory domain . Inorganic phosphate (Pi) potently inhibits hexokinase II and III, and at high concentrations (millimolar) is an inhibitor of hexokinase I. At relatively low concentrations (100 µM), however, Pi antagonizes the inhibition of hexokinase I by Glc-6-P[9]. Among all four isozymes, only Hexokinase III is substrate- inhibited by glucose at physiologically relevant concentrations (1 mM)[19-20].